• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Brian Daniels - Articles and news items

Bristol Myers Squibb logo

Bristol-Myers Squibb announces Retirement of Brian Daniels

Industry news / 7 May 2014 / Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company…

Bristol Myers Squibb logo

Bristol-Myers Squibb receives U.S. FDA breakthrough therapy designation for all-oral daclatasvir dual investigational regimen for chronic hepatitis C

Industry news / 24 February 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has granted its investigational DCV Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection…

Bristol Myers Squibb logo

Daclatasvir marketing authorization application for treatment of chronic hepatitis C validated for accelerated regulatory review by the European Medicines Agency

Industry news / 8 January 2014 / Bristol-Myers Squibb

Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4…

Bristol Myers Squibb logo

BMS submits first all-oral, interferon-free and ribavirin-free treatment regimen for regulatory review in Japan for patients with chronic hepatitis C infection

Industry news / 2 November 2013 / Bristol-Myers Squibb Company

“We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV…”

Bristol Myers Squibb logo

Promising phase IIb data on Clazakizumab in patients with moderate-to-severe rheumatoid arthritis to be presented

Industry news / 28 October 2013 / Bristol-Myers Squibb Company

Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor…

Bristol Myers Squibb logo

Promising phase IIb data on Clazakizumab in patients with moderate-to-severe Rheumatoid Arthritis to be presented

Industry news / 28 October 2013 / Bristol-Myers Squibb Company

Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine…

Bristol Myers Squibb logo

Bristol-Myers Squibb to present range of new hepatitis C data at the 2013 American Association for the study of liver diseases (AASLD) annual meeting

Industry news / 1 October 2013 / Bristol-Myers Squibb

Bristol-Myers Squibb Company (NYSE:BMY) announced today that 16 abstracts have been accepted for presentation at The Liver Meeting® 2013…

Bristol Myers Squibb logo

Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer

Industry news, News / 12 September 2013 / Bristol-Myers Squibb Company

Results from the Phase 3 randomized, double-blind clinical trial (Study 043)…

AstraZeneca

ONGLYZA® (saxagliptin) demonstrates no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial

Industry news, News / 2 September 2013 / AstraZeneca

SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments…

Bristol Myers Squibb logo
Bristol Myers Squibb logo

Bristol-Myers Squibb receives US FDA sNDA approval for use of SUSTIVA® (efavirenz)

Industry news, News / 3 May 2013 / Bristol-Myers Squibb Company

The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)…

Bristol Myers Squibb logo

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +